News

Patients with pretreated, HR-positive, HER2-negative metastatic breast cancer can now receive palbociclib (Ibrance) for use in combination with fulvestrant following the FDA’s recent approval of this new indication for the CDK 4/6 inhibitor.

The American Society of Clinical Oncology released its annual report, now in its 11th year, which documents the progress being made in clinical cancer research and identifies future research directions.

A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.

Group Health Research Institute in Seattle, Washington, has created an online tool for oncology professionals that lists prices for the 50 most commonly prescribed cancer treatment regimens.

A telephone triage service combined with patient education has helped to reduce cancer-related emergency department visits by 60% over 4 months, where it was piloted at a Florida health system, and it’s an approach researchers say can be easily replicated by other practices.

Feelings of social isolation and financial toxicity take an especially high toll on patients with LAHNC, and assessing patients for these issues is essential to achieve optimal care.

Collaboration to feature content from one of nation’s leading nursing school programs.

Focusing on a fiber-rich diet at a young age may help lower the risk of developing breast cancer later, according to findings of a new study.

The American Society of Clinical Oncology recently released the 40-page Cuidado del Paciente, the Spanish version of Caregiving.

A paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors, and increased dialogue between healthcare providers and YAs has the potential to empower this population at risk for adverse financial and psychosocial outcomes, and steer them towards reputable sources of financial support.

After reports of patient deaths related to intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 trial, the FDA has placed a “full clinical hold” on trials exploring the tyrosine kinase inhibitor pacritinib.

Newly described research reports an upward trend in the proportion of patients with NSCLC classified as never-smokers.

One of the most commonly-affected areas of life impacted by disease and treatment

At the end of January 2016, 69 National Cancer Institute-designated cancer centers issued a statement urging parents, young adults and physicians to increase HPV vaccination rates.

Fosaprepitant dimeglumine (Emend for injection) received FDA approval as a single-dose in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

The theme of World Cancer Day this year is

Decision Making and Experiences with Mastectomy for Managing Breast Cancer Risk in Women at High Risk for Breast Cancer

CancerCare is pleased to announce the availability of co-payment assistance for people diagnosed with multiple myeloma through the CancerCare Co-Payment Assistance Foundation.

Androgen-deprivation therapy, while an effective treatment for prostate cancer, can result in side effects and a reduced quality of life.

A mandate enacted after the 2010 Patient Protection and Affordable Care Act (ACA) was supposed to improve health coverage for patients enrolled in clinical trials.

The word

Individuals with detectable human papillomavirus (HPV)-16 in their mouthwash samples were 22 times more likely to develop oropharyngeal cancer (OPC) than those without the type of virus, according to findings of a new study.

The FDA has approved eribulin mesylate (Halaven) to treat patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

Results of a recent study show that patients, caregivers, healthcare providers, and members of the general public have stronger negative attitudes toward lung cancer compared with breast cancer.

The American Cancer Society and American Society of Clinical Oncology collaborated to create survivorship guidelines to assist primary care and other clinicians in the care of women with breast cancer.

Results from clinical trials presented at the 2016 Gastrointestinal Cancers Symposium signal a role for the immunotherapy nivolumab (Opdivo) in the treatment of GI malignancies.